Navigation Links
genae Appoints Chief Medical Officer
Date:4/16/2012

ANTWERP, Belgium, April 16, 2012 /PRNewswire/ --

genae, a leading Contract Research Organization (CRO) and services provider for the medical device industries, today announced that Catalina Trana, MD, has been appointed Chief Medical Officer. In this role, Dr. Trana will be responsible for all clinical, safety and risk management related to genae's research services.

"I am delighted to welcome Catalina, whose extensive clinical and research expertise will be of great benefit to the many aspects of our services offering," said Bart Segers, Chairman and CEO of genae. "We believe that her experience as an interventional cardiologist provides her with a unique opportunity to view our services with an unsurpassed balance of clinical insight, business acumen and regulatory and safety compliance.

Dr. Trana holds the position of Cardiology Specialist at the Interventional Cardiology Department of the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. She was a fellow at the Cardiovascular Center Aalst, OLVZ, Aalst, Belgium and worked and trained at the Interventional Cardiology Department and Cardiovascular Surgical Department of the Cardiovascular Center in Iasi, Romania; and at the Catholic University of Leuven, Belgium. Her scientific and research work is illustrated by peer-reviewed publications and presentations during international congresses and symposia.

About genae

genae is a full service CRO and an innovative services provider for the medical industries and aims at improving health and quality of life by innovating and accelerating high quality research. The group is ISO 9001 certified for Clinical Trial Management, Core Laboratory Services and Additional Services for the Medical Industries.

genae associates nv is a privately held company with principal offices in Antwerp, Belgium.

genae Americas Inc. is a privately held company with principal offices in Cleveland, OH.

Please visit: http://www.genae.com

Company Contact

genae associates nv
Justitiestraat 6B
2018 Antwerp, Belgium
Aly Talen, RN
Sr. VP Business Development
+32-3-290-03-06
aly.talen@genae.com

genae Americas Inc.
Global Cardiovascular Innovation Center
10000 Cedar Avenue
Cleveland, OH 44106, USA
Dimitri Buytaert, PT CCRA
President
+1-216-445-4535
dimitri.buytaert@genae.com


'/>"/>
SOURCE genae associates nv
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
2. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
3. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
4. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
6. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
7. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
11. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone ... tool that shows how a cleanroom works. The ... discussions about science and technology. ... "As a technology company, SSF enthusiastically supports the ... help educators foster the next generation of innovators. ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... In an ... today GrassrootsHealth, a public health promotion and research organization, declared May as “National ... society, and other shifts in cultural behavior over the past several decades, Americans ...
(Date:5/4/2016)... ... May 04, 2016 , ... ProList is a set of ... . With ProList, editors can easily create lists for presentations, youtube productions, and ... bullet points. ProList is the perfect complement to presentation style videos. , ProList ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... engineer of patented products, announces the Everlasting Glove, a sports invention that aids ... Athletic and Sporting Goods Manufacturing industry is worth $9 billion," says Scott Cooper, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, ... patent for its innovative Secure Messaging platform, which includes secure, private messaging, large ... patent extends Cirius’s portfolio of patents around innovative features for securing, tracking, and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare ... today announced it has secured $9 million in Series A funding led by ... investment will be used by Somnoware to further fulfill its mission to connect, ...
Breaking Medicine News(10 mins):